Human iPSC-Derived Endothelial Cells Exhibit Reduced Immunogenicity in Comparison With Human Primary Endothelial Cells.

Human induced pluripotent stem cell (iPSC)-derived endothelial cells (ECs) have emerged as a promising source of autologous cells with great potential to produce novel cell therapy for ischemic vascular diseases. However, their clinical application still faces numerous challenges including safety concerns such as the potential aberrant immunogenicity derived from the reprogramming process. This study investigated immunological phenotypes of iPSC-ECs by a side-by-side comparison with primary human umbilical vein ECs (HUVECs).

Reliability and Criterion Validity of Physio Master Application for the Measurement of Cervical Range of Motion in Healthy Individuals.

Objective:  Recent advances in smartphone applications for measuring range of motion have led to the development of the physio master application by Trinus Laboratory, Navi Mumbai. This app, equipped with a magnetometer and accelerometer, accurately measures the angle between starting and ending device positions. This study aimed to assess the inter-rater and intra-rater reliability, as well as the criterion validity, of the physio master application in measuring cervical range of motion in healthy individuals.

Cost-Minimization Model in Cryptogenic Stroke: ePatch vs Implantable Loop Recorder in Patients from the UK, Netherlands, and Sweden.

Background: Patients who have experienced a cryptogenic stroke (CS) may benefit from extended monitoring and possible earlier detection of atrial fibrillation (AF), allowing for the timely initiation of appropriate pharmacotherapy.

Objective: This economic study aimed to evaluate the clinical and cost outcomes of using mid-term cardiac monitors (referred to as "ePatch") versus ILR-only in post-CS patients in the UK, Netherlands (NL) and Sweden.

Methods: An existing cost-minimization model was modified to fit healthcare settings in the UK, Netherlands and Sweden.

Collaborative study for the establishment of Golimumab Biological Reference Preparation Batch 1.

A candidate preparation of the fully human anti-tumour necrosis factor (TNF) monoclonal antibody golimumab was formulated and lyophilised at the Medicines and Healthcare products Regulatory Agency (MHRA) prior to evaluation in a collaborative study for its suitability to serve as a World Health Organization (WHO) International Standard (IS)/European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) for the potency assay of golimumab.